PreciseDx
Visible Intelligence develops PreciseBreast™, a visual AI-analysis tool that classifies breast cancer patients into low and high-risk cohorts based on tissue sample morphology, generating results in approximately 48 hours. This technology addresses the issue of subjective tumor grading and lengthy gene expression testing, enabling faster, data-informed decision-making for oncologists and reducing patient anxiety.
- Artificial Intelligence
- Digital Health
- Healthcare Technology
- Software Only
Funding
Raised to date
$31.5MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Founder details are not available yet.
Product
Problem
Current breast cancer tumor analysis relies on subjective grading methods, leading to inconsistent risk assessments. Gene expression testing provides additional information but is expensive, time-consuming, and can still be ambiguous. This can result in delayed treatment decisions and increased patient anxiety.
Solution
Visible Intelligence's PreciseBreast™ is a visual AI-analysis tool that objectively classifies breast cancer patients into low- and high-risk cohorts based on tissue sample morphology. The Morphology Feature Array® combines visual analysis of pathology slides with clinical features in a proprietary algorithm to predict recurrence risk. PreciseBreast™ generates a single Risk Score between 0 and 100, providing clear risk stratification in approximately 48 hours. This enables faster, data-informed decision-making between patients and their oncology care team, complementing both pathologist’s tumor grading and gene expression testing.
Target Audience
PreciseBreast™ benefits oncologists, surgeons, pathologists, payors, and patients by powering the process of diagnosis and cancer care planning.
Features
- Visual AI-analysis of tissue samples to identify key morphologic factors
- Proprietary algorithm combining morphologic and clinical features
- Objective risk stratification into low- and high-risk cohorts
- Rapid report generation in approximately 48 hours
- Single Risk Score between 0 and 100 for clear and consistent risk assessment